Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | TACR2 | P21452 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1086519 | 0.86 | MEN1 (0.46) | GRM2SMN1; SMN2LMNATACR2TACR1 | |
| SCHEMBL1086606 | 0.83 | ALDH1A1 (0.48) | SMN1; SMN2LMNA | |
| SCHEMBL1086607 | 0.82 | TSHR (0.47) | GRM2SMN1; SMN2HSD11B1LMNATSHR | |
| SCHEMBL1086223 | 0.82 | HSD11B1 (0.50) | HSD11B1LMNATSHR | |
| SCHEMBL1086845 | 0.81 | TSHR (0.46) | GRM2SMN1; SMN2HSD11B1LMNATSHR | |
| SCHEMBL1086846 | 0.81 | TSHR (0.43) | GRM2SMN1; SMN2HSD11B1LMNATSHR | |
| SCHEMBL1086588 | 0.81 | RAB9A (0.54) | SMN1; SMN2LMNA | |
| SCHEMBL1085966 | 0.81 | USP2 (0.51) | SMN1; SMN2TSHR | |
| SCHEMBL1085986 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAGRIN1GRIN2B | |
| SCHEMBL1086224 | 0.78 | SMN1; SMN2 (0.43) | SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | GRUENENTHAL GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | DDO, DAO, OTC | GRM2 389/4885SMN1; SMN2 3067/4885HSD11B1 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.